CD274 and non-small cell lung carcinoma: If confirmed in larger clinical trials, these findings may represent a novel therapeutic approach of immunotherapy rechallenge in NSCLC patients with an anti-PD-L1 drug, avelumab, in combination with and anti-EGFR drug, cetuximab, after progression to anti-PD-1 mAbs.